AU2006235260A1 - ADAM10 in cancer diagnosis, detection and treatment - Google Patents

ADAM10 in cancer diagnosis, detection and treatment Download PDF

Info

Publication number
AU2006235260A1
AU2006235260A1 AU2006235260A AU2006235260A AU2006235260A1 AU 2006235260 A1 AU2006235260 A1 AU 2006235260A1 AU 2006235260 A AU2006235260 A AU 2006235260A AU 2006235260 A AU2006235260 A AU 2006235260A AU 2006235260 A1 AU2006235260 A1 AU 2006235260A1
Authority
AU
Australia
Prior art keywords
cancer
cell
antibody
adam10
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2006235260A
Other languages
English (en)
Inventor
Robert Booher
Abdallah Fanidi
Albert Lai
Marc Malandro
Edward Moler
Michael Rowe
Christin Tse
Xie Xu
Guoying Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Sagres Discovery Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Sagres Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc, Sagres Discovery Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of AU2006235260A1 publication Critical patent/AU2006235260A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2006235260A 2005-04-07 2006-04-07 ADAM10 in cancer diagnosis, detection and treatment Withdrawn AU2006235260A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66986205P 2005-04-07 2005-04-07
US60/669,862 2005-04-07
PCT/US2006/013156 WO2006110583A2 (en) 2005-04-07 2006-04-07 Adam10 in cancer diagnosis, detection and treatment

Publications (1)

Publication Number Publication Date
AU2006235260A1 true AU2006235260A1 (en) 2006-10-19

Family

ID=37087563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006235260A Withdrawn AU2006235260A1 (en) 2005-04-07 2006-04-07 ADAM10 in cancer diagnosis, detection and treatment

Country Status (6)

Country Link
US (1) US20090297507A1 (enExample)
EP (1) EP1896580A2 (enExample)
JP (1) JP2008535854A (enExample)
AU (1) AU2006235260A1 (enExample)
CA (1) CA2604883A1 (enExample)
WO (1) WO2006110583A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101485163B1 (ko) 2012-02-21 2015-01-23 고려대학교 산학협력단 메탈로프로테이즈 ａｄａｍ１７에 의한 도파민성 신경세포로의 분화 조절 조성물
US20160040126A1 (en) * 2012-02-21 2016-02-11 Korea University Research And Business Foundation Regulation of differentiation into dopaminergic neurons by metalloprotease
MX2020004218A (es) 2017-10-02 2020-11-11 Verra Therapeutics Métodos y composiciones para inhibir las actividades biológicas de adam10.
US12247232B2 (en) 2018-01-31 2025-03-11 Verra Therapeutics, Inc. Methods and compositions for inhibiting ADAM 9 biological activities
CN113588940B (zh) * 2021-07-30 2023-05-12 菲鹏生物股份有限公司 一种提高间接标记灵敏度的方法和试剂盒
CN118987232A (zh) * 2024-08-08 2024-11-22 武汉科技大学 靶向cd30的car-t细胞与adam10抑制剂联合制备治疗cd30阳性淋巴瘤的药物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003237532B2 (en) * 2002-06-12 2009-07-30 Symphony Evolution, Inc. Human ADAM-10 inhibitors

Also Published As

Publication number Publication date
WO2006110583A2 (en) 2006-10-19
JP2008535854A (ja) 2008-09-04
CA2604883A1 (en) 2006-10-19
EP1896580A2 (en) 2008-03-12
WO2006110583A3 (en) 2007-04-26
US20090297507A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
US20070237770A1 (en) Novel compositions and methods in cancer
WO2006110581A2 (en) Cancer-related genes
EP2062591A1 (en) CACNA1E in cancer diagnosis detection and treatment
AU2004276821A1 (en) Novel therapeutic targets in cancer
AU2003299646B2 (en) Novel therapeutic targets in cancer
AU2006235271B2 (en) SEMA4D in cancer diagnosis, detection and treatment
US20070098728A1 (en) Novel compositions and methods in cancer
JP4942219B2 (ja) 癌の診断、検出および処置におけるｄｄｒ２
US20090297507A1 (en) ADAM10 in Cancer Diagnosis, Detection and Treatment
CA2563367A1 (en) Novel compositions and methods in cancer
EP2204376A2 (en) Novel therapeutic targets in cancer
US20090317391A1 (en) Cancer Related Genes (PTPE)
AU2005262348A1 (en) Novel compositions and methods in cancer

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE CO-INVENTORS NAME TO READ MARC MALANDRO

MK12 Application lapsed section 141(1)/reg 8.3(2) - applicant filed a written notice of withdrawal